A randomized phase II trial of postoperative adjuvant therapy with imatinib for 1 Year versus 6 months in patients with gastrointestinal stromal tumors
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 23 Dec 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2013 Interim results presented at the 2013 Gastrointestinal Cancers Symposium.
- 21 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.